All

Blog Post
8/28/2008
Posted by John M. Simpson
Suppose you made two drugs that did the same thing, but one sold for $60 a month and the other for $2,000.  Wouldn't you want to know if they were equally effective? Not if you're Genentech. Those folks would rather bury their heads in the sand and maximize their profits. Here's the deal:  Age-related Macular Degeneration (AMD) is one of...
Blog Post
8/27/2008
Posted by John M. Simpson
Stanford University's decision to curtail drug and medical device company financing of its continuing medical education (CME) programs is a major step toward ensuring doctors practice medicine based on science, not marketing plans. In announcing the new policy medical school Dean Philip Pizzo said: “I want to be able to honor the public...
Archived Article
8/22/2008
Consumer Watchdog
[Editor’s note: When 15-year-old Dawn Marie Esposito of Lincoln Park, N.J., was hospitalized with a head injury after a car accident, doctors assured her parents that it wasn’t potentially fatal. But days later, she suddenly and “inexplicably” died. It was only later, after seeking legal help, that they found out the likely...
News Release
6/17/2008
CONTACT Jerry Flanagan, cell: 310-889-4912; or Carmen Balber, 310-392-0522, ext. 324
Consumer Watchdog Hails Assembly Push Against Sale of Patients' Prescription Information to Marketers; "Big Pharma's Lobbying Steamroller Is Out of Gas," Says Advocate. Sacramento, CA -- A bill allowing marketers hired by drug companies to secretly access patient prescription drug records failed to get a single ‘yes’ in a key...
Blog Post
6/3/2008
Posted by John M. Simpson
Call it Big Pharma U.  It's the commonplace practice of drug companies and medical device manufacturers to flood medical schools with millions of dollars in cash, gifts and free samples. Now there are encouraging signs the abuses may be ending. In April a Task Force of the American Association of Medical Colleges issued a report urging tough...
News Release
5/29/2008
CONTACT CONTACT: Jerry Flanagan, cell: (310) 889-4912
Santa Monica, CA -- The California Senate passed a bill today that will allow marketing firms, like bill sponsor Adheris, to gain access to a patient's private prescription drug records without their knowledge.  The bill will now be considered by the state Assembly. Bill sponsor Adheris Inc, previously Elensys, changed its name in 2004...
News Release
5/22/2008
CONTACT CONTACT: Jerry Flanagan, (310) 392-0522, ext. 319
Bill Sponsor Adheris Changed Its Name After Privacy Violations, Washington Post Santa Monica, CA -- The California Senate rejected a bill today sponsored by a drug marketing firm that was forced to change its name after privacy violations. See Washington Post coverage below. The bill, SB 1096 (Calderon), which was granted a second chance to pass...
Blog Post
5/9/2008
Posted by Judy Dugan
Consumer Watchdog has protested strings-attached grants from Big Oil to universities, including clauses that allow corporate control of patents and secret offices on campus. Oil companies took lessons from the agricultural industry's history at land-grant colleges, but the real corporate pioneers of this tactic were drug companies. Here, from the...
Blog Post
5/2/2008
Posted by Carmen Balber
Here's a perfect example of why a non-medical company with no relationship to the patient should never be allowed access to patient information without permission first - as a bill that advanced in the Senate this week would allow. Information on thousands of UCSF patients was accessible on the Internet for more than three months last year, a...
Blog Post
5/2/2008
Posted by Carmen Balber
A bill passed its second California Senate committee this week that would give an ever-wider circle of companies access to Californians' private medical information. SB 1096 by Senator Ron Calderon would allow pharmacies to give patients’ medication histories to third-party marketing companies, without the patient’s knowledge or...